Clinical Trials

DermatologicGenitourinaryGynecologicHead & NeckThoracic

35 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms

NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

GastrointestinalHead & Neck

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03040999 2026-02-04

KEYNOTE-412

Phase 3 Completed

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

78 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT03978689 2026-01-22

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

80 enrolled

Head and Neck Neoplasms

NCT02296684 2026-01-15

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

67 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Phase 3 Completed

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

59 enrolled 9 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04260126 2025-10-01

VERSATILE002

95 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05271604 2025-09-26

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

42 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04180215 2025-09-15

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

198 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Neoplasms, Squamous Cell

NCT06771674 2025-09-09

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Completed

662 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

DermatologicGenitourinaryHead & NeckThoracic

146 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

260 enrolled 52 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT02358031 2025-07-18

MK-3475-048

Phase 3 Completed

882 enrolled 50 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04555837 2025-05-20

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

24 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02289209 2025-03-06

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

48 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03058289 2025-02-27

IT-01

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03245489 2025-01-31

Anti-platelet + Pembro for H&N Tumors

20 enrolled

Phase EARLY_PHASE1 Completed

Head and Neck Neoplasms

NCT04188951 2024-12-04

HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer

10 enrolled

Head and Neck Neoplasms

NCT02609503 2024-11-05

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

29 enrolled 27 charts

Head and Neck Neoplasms

NCT03666273 2024-05-28

Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.

60 enrolled

Phase EARLY_PHASE1 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06413095 2024-05-14

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

13 enrolled

Head & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Sarcoma

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

132 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT03511391 2024-01-23

CHEERS

DermatologicGenitourinaryHead & NeckThoracic

99 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

37 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03695510 2022-04-21

ALPHA

29 enrolled

Head and Neck Neoplasms

NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

159 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers